Rituximab for anti-MAG neuropathy in specific patients
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Immune system & allergy clinical trials.
This Phase 3 study tests rituximab, an antibody medicine, for people with a particular type of nerve damage called anti-MAG–related demyelinating polyneuropathy. It aims to see if rituximab improves symptoms or function in patients who are considered “good responders.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have IgM-related blood condition: MGUS or Waldenström macroglobulinemia (WM)
- Your nerve disease fits chronic inflammatory demyelinating polyneuropathy on nerve testing, with an anti-MAG level of at least 10,000 BTU
- Your symptoms have worsened within the last 24 months, and the total time having the disease is 5 years or less
- You have not taken immune-related medicines recently (no immunoglobulin in the last 3 months; no immunosuppressive therapy or long-enough steroid treatment in the last 6 months)
- Your main blood counts are high enough (white blood cells ≥ 1500 and platelets ≥ 75,000)
- You can safely take rituximab: no prior rituximab, no severe allergy to similar antibody medicines, and no significant uncontrolled heart/lung/kidney/liver disease or serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a specific type of light therapy (photobiomodulation) can improve symptoms of nerve damage (peripheral neuropathy) caused by anti-MAG antibodies. If you have this condition, this trial might offer a new way to manage your symptoms.
This study looks at how nerves work and their structure in people with Charcot-Marie-Tooth disease, CIDP, or anti-MAG neuropathy. It may help doctors better understand these conditions.
This study looks at a treatment made from immune proteins (immunoglobulin M) to treat neuropathy caused by anti-MAG antibodies. It may help improve nerve symptoms in people with this specific type of nerve condition.
This trial tests whether the oral drug zanubrutinib can help people with anti-MAG antibody polyneuropathy, a nerve condition often linked to certain blood cancers. It aims to improve nerve symptoms by targeting the immune cells responsible.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
Hear when a new Anti-MAG Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.